Dosing for RVX-208 Phase 1a Clinical Study Completed

Calgary, Canada (ots/PRNewswire) -

- Phase 1a Study Objectives Were Met

- TSX Exchange Symbol: RVX

Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX)
announced today that it has completed dosing of its Phase 1a safety,
tolerability and pharmacokinetics study for its lead drug candidate,
RVX-208, which addresses the dyslipidemia market. "Initial results
from the emerging data are very good," declared Donald J. McCaffrey,
President & CEO of Resverlogix. "As reported earlier this year the
most remarkable results from this study continue to be the
outstanding pharmacokinetics (drugability) of RVX-208. With these
successful results in hand we are now planning for our Phase 1b/2a
trial which, pending discussions and approval from the FDA, we expect
to start later this year."

The primary objectives of the Phase 1a trial were to examine the
safety, tolerability and pharmacokinetics of RVX-208. This study
successfully met those objectives. In addition to the completed Phase
1a human clinical trial, RVX-208 has been the subject of 126
preclinical studies to date, comprising safety, toxicity,
pharmacokinetics and pharmacology studies. The Company has selected
the dosages to be used in the 28-day Phase 1b/2a study.

"We are very pleased with these promising results which indicate
that RVX-208 is a safe and well tolerated drug," stated Dr. Jan
Johansson, MD, PhD, Senior Vice President Medical Affairs of
Resverlogix. "We are in the process of finalizing the tables, figures
and legends for this past study." A review of the pharmacokinetic
data was recently presented at the Arteriosclerosis, Thrombosis and
Vascular Biology conference in Atlanta, GA.

About Cardiovascular Disease (CVD)

CVD can be generally defined as any abnormal condition
characterized by dysfunction of the heart and blood vessels. CVD
includes atherosclerosis (especially coronary heart disease which can
lead to heart attacks), cerebrovascular disease (stroke), and
hypertension (high blood pressure). The underlying cause of most CVD
is a gradual clogging of the arteries (atherosclerosis) that supply
blood to the heart, brain and other vital organs.

The American Heart Association estimates that almost 80 million
American Adults have one or more types of cardiovascular disease. CVD
remains the number one killer of developed nations. Nearly 2400
Americans die each day from cardiovascular disease - that is 1 person
will die every 36 seconds.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in
the development of novel therapies for important global medical
markets with significant unmet needs. The NexVas(TM) program is the
Company's primary focus which is to develop novel small molecules
that enhance ApoA-I. These vital therapies address the grievous
burden of atherosclerosis and other important diseases such as acute
coronary syndrome, diabetes, Alzheimer's and other vascular
disorders. The Company's secondary focus is TGF-Beta Shield(TM), a
program that aims to address burgeoning grievous diseases, such as
cancer and fibrosis. Resverlogix Corp. trades on the Toronto Stock
Exchange (TSX:RVX). For further information please visit
http://www.resverlogix.com.

This news release may contain certain forward-looking statements
that reflect the current views and/or expectations of Resverlogix
Corp. with respect to its performance, business and future events.
Such statements are subject to a number of risks, uncertainties and
assumptions. Actual results and events may vary significantly. The
TSX Exchange does not accept responsibility for the adequacy or
accuracy of this news release.

For further information:
Theresa Kennedy, VP, Corporate Communications, Resverlogix Corp.,
Phone: +1-604-538-7072,
Fax: +1-403-256-8495,
Email: Theresa@resverlogix.com;
Sarah Zapotichny, Manager, Investor Relations, Resverlogix Corp.,
Phone: +1-403-254-9252,
Fax: +1-403-256-8495,
Email: Sarah@resverlogix.com;
Website: http://www.resverlogix.com

ots Originaltext: Resverlogix Corp.
Im Internet recherchierbar: http://www.presseportal.de

Contact:
For further information: Theresa Kennedy, VP, Corporate
Communications, Resverlogix Corp., Phone: +1-604-538-7072, Fax:
+1-403-256-8495, Email: Theresa@resverlogix.com; Sarah Zapotichny,
Manager, Investor Relations, Resverlogix Corp., Phone:
+1-403-254-9252, Fax: +1-403-256-8495, Email: Sarah@resverlogix.com